CIA
ABCL icon

Cape Investment Advisory’s AbCellera Biologics ABCL Stock Holding History

Cape Investment Advisory’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.92K Buy
+500
New +$2.44K ﹤0.01% 1091

Other funds holding ABCL

CMF
Counterpoint Mutual Funds San Diego, California $1.01B AUM 37.65% 1-Year Est. Return
DRP
Decker Retirement Planning Levi, Utah $294M AUM 97.44% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return
HOWA
Heritage Oak Wealth Advisors Santa Rosa Beach, Florida $340M AUM 29.73% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
FA
Fedenia Advisers Madison, Wisconsin $421M AUM 96.46% 1-Year Est. Return
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.49% 1-Year Est. Return
NA
Networth Advisors Canonsburg, Pennsylvania $172M AUM

Cape Investment Advisory's ABCL Position: Q2 2026 in Review

Cape Investment Advisory opened a new position in AbCellera Biologics (ABCL) in Q2 2026: 500 shares worth $3.92K. The stake represents ﹤0.01% of the portfolio and ranks #1091 among its holdings.

20 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Cape Investment Advisory held 500 shares of AbCellera Biologics worth $3.92K as of Q2 2026.
  • AbCellera Biologics was a new Cape Investment Advisory position in Q2 2026.
  • AbCellera Biologics made up ﹤0.01% of Cape Investment Advisory's portfolio in Q2 2026, its #1091 holding.
  • 20 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Cape Investment Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.